BioCentury
ARTICLE | Company News

CSL, Zenyth deal

September 18, 2006 7:00 AM UTC

Under CSL’s previously announced acquisition of ZTL for A$0.82 per share, or about A$102.7 million (US$77.3 million) in cash, the companies proposed to cancel all outstanding ZTL options for A$0.01-A$...